Ban on Methylcobalamin to be revoked as FSSAI scientific panel approves Vitamin B12 as nutraceuticals

Industry finally heaves a sigh of relief as ban on manufacturing methylcobalamin in Gujarat would soon be revoked as Methylcobalamin (Vitamin B12) has been approved by the the Food Safety and Standards Authority of India (FSSAI) scientific panel as nutraceuticals.

In June 2019, the manufacturers of Gujarat were taken aback when a letter was issued by Food and Drug Control Administration (FDCA) commissioner, Gujarat to ban methylcobalamin.

Last week, the Central Drugs Standard Control Organisation (CDSCO) had urged FSSAI to take action against Gujarat-based manufacturers for manufacture and sale of methylcobalamin meant for therapeutic intervention in contravention of norms.

In a letter to the FSSAI, CDSCO had brought to the notice that various brands of product containing methylcobalamin are manufactured and sold having therapeutic intervention under the FSSAI license.

Methylcobalamin also known as mecobalamin or methyl B12 plays a key role in maintaining good health. It is the only form of vitamin B12 that can cross the blood brain barrier without bio-transformation.

Its methyl group stimulates serotonin secretion, a neuro-transmitter which is responsible for mood enhancement and protects brain from damage against excitatory neurotransmitters.

“Repeated correspondences by industry experts since June 2019 when the ban was invoked has finally yielded the desired outcome from Central Drugs Standard Control Organisation (CDSCO), Food Safety and Standards Authority of India (FSSAI) and Gujarat state drug control department,” says pharma consultant Dr Sanjay Agrawal.

The letter further states that such decisions are taken by FSSAI’s scientific panel after risk assessment based on secondary data which then goes through a process of approval through scientific committee and the union ministry of health. We will expedite it and notify it shortly.

Related Posts

India eyes Russia, Brazil, Netherlands for pharma export growth

New Delhi: India plans to increase pharmaceutical exports to Russia, the Netherlands and Brazil, according to two industry sources aware of the matter, aiming to expand its presence beyond the…

NPPA fixes retail price of 42 new drugs

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 42 new drugs as per the provisions of the Drugs Prices Control Order (DPCO), 2013, including…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India eyes Russia, Brazil, Netherlands for pharma export growth

India eyes Russia, Brazil, Netherlands for pharma export growth

Vibrant Gujarat regional conference to showcase North Gujarat’s pharma sector strength: Gujarat govt

Vibrant Gujarat regional conference to showcase North Gujarat’s pharma sector strength: Gujarat govt

Zydus launches VaxiFluTM India’s first trivalent influenza vaccine

Zydus launches VaxiFluTM India’s first trivalent influenza vaccine

NPPA fixes retail price of 42 new drugs

NPPA fixes retail price of 42 new drugs